TASIN-1 |
Katalog-Nr.GC11469 |
TASIN-1 ist ein selektiver Inhibitor des verkÜrzten APC-Gens (Gen fÜr adenomatÖse Polyposis coli) und Übt zytotoxische Wirkungen durch Hemmung der Cholesterinbiosynthese aus. TASIN-1 stellt eine potenzielle therapeutische Strategie zur PrÄvention und Intervention bei CRC mit mutiertem APC dar.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 792927-06-1
Sample solution is provided at 25 µL, 10mM.
TASIN-1 is a small molecule inhibitor of mutant adenomatous polyposis coli (APC) [1].
Adenomatous polyposis coli (APC) is a multifunctional tumor suppressor gene that is mutated in more than 80% of colon tumors. APC plays an important role in the negative regulation of canonical WNT signaling pathway through proteasomal degradation of b-catenin. APC is involved in cell cycle control, migration, differentiation, and apoptosis [1].
TASIN-1 is a selective inhibitor of mutant APC. In two authentic human CRC cell lines HCT116 (WT APC) and DLD1 (truncated APC1417), TASIN-1 exhibited potent and selective toxicity toward DLD1 cells with IC50 value of 70 nM but not toward HCT116 cells (IC50 >50 μM). TASIN-1 also reduced the endogenous cholesterol biosynthesis rate. TASIN-1 exerted its killing effects primarily by depleting cholesterol through inhibition of emopamil-binding protein (EBP) activity. However, knockdown of truncated APC (>90%) expression desensitized DLD1 cells to TASIN-1, suggesting that APC is required for TASIN-1's cytotoxicity [1].
In nude mice with established DLD1 and HT29 tumors, intraperitoneal injection of TASIN-1 twice daily for 18 days reduced the size of tumor xenografts and tumor growth rates. TASIN-1 resulted in the appearance of apoptotic cells with fragmented nuclei and induced an increase in cleaved caspase 3 and cleaved PARP1. However, TASIN-1 did not inhibit tumor growth in HCT116 (WT APC) xenografts. In a genetically engineered CRC mouse model, TASIN-1 significantly reduced tumor formation in the colons of CPC;Apc mice [1].
Reference:
1.Lu Zhang, Panayotis C. Theodoropoulos, Ugur Eskiocak, et al. Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer. Science Translational Medicine 19 Oct 2016: Vol. 8, Issue 361, pp. 361ra140.
Average Rating: 5
(Based on Reviews and 39 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *